(thirdQuint)A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine.

 This was a prospective, randomized, double-blind, placebo-controlled release study.

 Eligible subjects were randomly assigned in a 4:1 fashion to receive a single dose of trivalent vaccine or placebo by intranasal spray.

 Randomization was stratified by site.

 Each subject received 1 dose of study vaccine on Study Day 0.

 The duration of study participation for each subject was the time from study vaccination through 180 days after study vaccination.

.

 A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine@highlight

This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using a new strain recommended for the 2008-2009 influenza season not previously contained in the trivalent intranasal FluMist vaccine.

 Three hundred healthy adults received a single dose of vaccine or placebo and were followed for 180 days.

